1-(3-(3,6-difluoro-9H-carbazol-9-yl)-2-hydroxypropyl)piperidin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(3-(3,6-difluoro-9H-carbazol-9-yl)-2-hydroxypropyl)piperidin-2-one
• 英文别名: 1-(3-(3,6-difluoro-9H-carbazol-9-yl)-2-hydroxypropyl) piperidin-2-one；1-[3-(3,6-difluorocarbazol-9-yl)-2-hydroxypropyl]piperidin-2-one
• 化学式: C₂₀H₂₀F₂N₂O₂
• 分子量: 358.388
• InChiKey: GTYLNENMAJWOPX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  45.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-氯-4-氟苯胺 在 potassium tert-butylate 、 palladium diacetate 、 potassium carbonate 、 tricyclohexylphosphine tetrafluoroborate 、 potassium hydroxide 、 tri tert-butylphosphoniumtetrafluoroborate 作用下， 以 N,N-二甲基乙酰胺 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 30.17h， 生成 1-(3-(3,6-difluoro-9H-carbazol-9-yl)-2-hydroxypropyl)piperidin-2-one
  参考文献：
  名称：

  含咔唑的酰胺和脲：发现隐花色素调节剂作为降糖药

  摘要：

  合成了一系列新型的含咔唑的酰胺和脲。这些化合物的结构-活性关系研究导致了强效隐色调节剂的鉴定。基于所需的药代动力学/药效学参数和在db / db小鼠中的功效研究结果，选择化合物50进行进一步分析。

  DOI：

  10.1016/j.bmcl.2017.12.051

文献信息

• CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS
  申请人：ReSet Therapeutics, Inc.

  公开号：US20150284362A1

  公开（公告）日：2015-10-08

  The subject matter herein is directed to carbazole-containing amide, carbamate, and urea derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , A, D, E, G, J, L, M, Q, a, and b are accordingly described. Also provided are pharmaceutical compositions containing the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, complications associated with diabetes, Cushing's syndrome, NASH, NAFLD, asthma, and COPD.

  本文涉及含有咔唑基的酰胺、碳酸酯和脲衍生物，以及其结构式I中的药用可接受盐或水合物，其中变量R1、R2、R3、R4、R5、R6、R7、A、D、E、G、J、L、M、Q、a和b分别描述。还提供了含有式I化合物的药物组合物，用于治疗Cry介导的疾病或紊乱，如糖尿病、与糖尿病相关的并发症、库欣综合征、NASH、NAFLD、哮喘和COPD。
• Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators
  申请人：ReSet Therapeutics, Inc.

  公开号：US10005759B2

  公开（公告）日：2018-06-26

  The subject matter herein is directed to carbazole-containing amide, carbamate, and urea derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R1, R2, R3, R4, R5, R6, R7, A, D, E, G, J, L, M, Q, a, and b are accordingly described. Also provided are pharmaceutical compositions containing the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, complications associated with diabetes, Cushing's syndrome, NASH, NAFLD, asthma, and COPD.

  本文的主题涉及结构式 I 的含咔唑的酰胺、氨基甲酸酯和脲衍生物及其药学上可接受的盐或水合物，其中相应地描述了变量 R1、R2、R3、R4、R5、R6、R7、A、D、E、G、J、L、M、Q、a 和 b。还提供了含有式 I 化合物的药物组合物，用于治疗 Cry 介导的疾病或紊乱，如糖尿病、糖尿病相关并发症、库欣综合征、NASH、NAFLD、哮喘和 COPD。
• [EN] CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS<br/>[FR] AMIDES, CARBAMATES ET URÉES CONTENANT DU CARBAZOLE EN TANT QUE MODULATEURS DE CRYPTOCHROME
  申请人：RESET THERAPEUTICS INC

  公开号：WO2015157182A1

  公开（公告）日：2015-10-15

  The subject matter herein is directed to carbazole-containing amide, carbamate, and urea derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R1, R2, R3, R4, R5, R6, R7, A, D, E, G, J, L, M, Q, a, and b are accordingly described. Also provided are pharmaceutical compositions containing the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, complications associated with diabetes, Cushing's syndrome, NASH, NAFLD, asthma, and COPD.
• Carbazole-containing amides and ureas: Discovery of cryptochrome modulators as antihyperglycemic agents
  作者：Paul S. Humphries、Ross Bersot、John Kincaid、Eric Mabery、Kerryn McCluskie、Timothy Park、Travis Renner、Erin Riegler、Tod Steinfeld、Eric D. Turtle、Zhi-Liang Wei、Erik Willis

  DOI：10.1016/j.bmcl.2017.12.051

  日期：2018.2

  A series of novel carbazole-containing amides and ureas were synthesized. A structure–activity relationship study of these compounds led to the identification of potent cryptochrome modulators. Based on the desired pharmacokinetic/pharmacodynamic parameters and the results of efficacy studies in db/db mice, compound 50 was selected for further profiling.

  合成了一系列新型的含咔唑的酰胺和脲。这些化合物的结构-活性关系研究导致了强效隐色调节剂的鉴定。基于所需的药代动力学/药效学参数和在db / db小鼠中的功效研究结果，选择化合物50进行进一步分析。